Get the Stockscreener App
174.61
0.26%
-0.45
After Hours:
175.21
0.60
+0.34%
Belite Bio Inc Adr stock is traded at $174.61, with a volume of 96,573.
It is down -0.26% in the last 24 hours and up +12.80% over the past month.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
See More
Previous Close:
$175.06
Open:
$175.84
24h Volume:
96,573
Relative Volume:
0.41
Market Cap:
$6.55B
Revenue:
-
Net Income/Loss:
$-32.61M
P/E Ratio:
-148.71
EPS:
-1.1742
Net Cash Flow:
-
1W Performance:
-2.09%
1M Performance:
+12.80%
6M Performance:
+140.08%
1Y Performance:
+218.17%
1-Day Range:
$173.19
$179.99
1-Week Range:
$168.00
$192.94
52-Week Range:
$49.00
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
174.61 | 6.57B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-26 | Initiated | BofA Securities | Buy |
| Jan-06-26 | Initiated | Morgan Stanley | Overweight |
| Dec-02-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-20-25 | Initiated | Mizuho | Neutral |
| Dec-14-23 | Initiated | Maxim Group | Buy |
| Jul-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-23 | Initiated | SVB Securities | Outperform |
| Aug-01-22 | Initiated | H.C. Wainwright | Buy |
| Jul-01-22 | Initiated | The Benchmark Company | Buy |
View All
Belite Bio Inc Adr Stock (BLTE) Latest News
Why (BLTE) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Belite Bio (NASDAQ:BLTE) Shares Down 5.2%Here's Why - MarketBeat
Belite Bio stock hits all-time high at 177.28 USD By Investing.com - Investing.com Nigeria
Belite Bio stock hits all-time high at 177.28 USD - Investing.com
Belite Bio (NASDAQ:BLTE) Reaches New 12-Month HighHere's What Happened - MarketBeat
Belite Bio (BLTE) Valuation Check As Phase 3 DRAGON Tinlarebant Data Presentations Approach - Sahm
Understanding Momentum Shifts in (BLTE) - Stock Traders Daily
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO) - markets.businessinsider.com
H.C. Wainwright reiterates Buy rating on Belite Bio stock with $185 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on Belite Bio stock with $185 target - Investing.com Nigeria
Belite Bio's (BLTE) Buy Rating Reiterated at HC Wainwright - MarketBeat
Belite Bio completes enrollment in phase 2/3 STGD1 drug trial - Investing.com India
Belite Bio Completes Global Enrollment in DRAGON II Tinlarebant Trial for Stargardt Disease - TipRanks
Belite Bio (NASDAQ:BLTE) Now Covered by Bank of America - Defense World
Belite Bio (NASDAQ:BLTE) Reaches New 1-Year HighStill a Buy? - MarketBeat
Belite Bio Surges on Breakthrough Eye Drug Hopes - TipRanks
Belite Bio stock hits all-time high at $170.35 - Investing.com
Belite Bio stock hits all-time high at $170.35 By Investing.com - Investing.com UK
BofA Securities initiates coverage on Belite Bio stock with Buy rating - Investing.com Canada
BofA Securities initiates coverage on Belite Bio stock with Buy rating By Investing.com - Investing.com South Africa
Avoiding Lag: Real-Time Signals in (BLTE) Movement - Stock Traders Daily
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
High Net Worth Advisory Group LLC Invests $259,000 in Belite Bio, Inc. Sponsored ADR $BLTE - Defense World
Assessing Belite Bio (BLTE) Valuation As Tinlarebant Progress And Pricing Plans Take Shape - Sahm
Dry Age Macular Degeneration Pipeline 2025: Key Companies, MOA, - openPR.com
Cantor Fitzgerald reiterates Overweight rating on Belite Bio stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight rating on Belite Bio stock - Investing.com
Belite Bio, Inc (BLTE) Stock Analysis: A Biotech Gem With 19.70% Upside Potential - DirectorsTalk Interviews
Discipline and Rules-Based Execution in BLTE Response - Stock Traders Daily
Belite Bio Reports Breakthrough Phase 3 Results for Stargardt Disease Treatment - MSN
Belite Bio stock hits all-time high at 169.88 USD By Investing.com - Investing.com Nigeria
Belite Bio stock hits all-time high at 169.88 USD - Investing.com
Morgan Stanley initiates Belite Bio stock with Overweight rating, $191 target - Investing.com Nigeria
Belite Bio (NASDAQ:BLTE) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Morgan Stanley initiates Belite Bio stock with Overweight rating, $191 target By Investing.com - Investing.com Canada
Belite Bio (NASDAQ:BLTE) Sets New 12-Month HighTime to Buy? - MarketBeat
Behavioral Patterns of BLTE and Institutional Flows - Stock Traders Daily
Belite Bio (NASDAQ:BLTE) Shares Up 5.5%Should You Buy? - MarketBeat
Belite Bio stock hits all-time high at 163.25 USD - Investing.com
Belite Bio stock hits all-time high at 163.25 USD By Investing.com - Investing.com Australia
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Short Interest Down 45.2% in December - MarketBeat
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Belite Bio (NASDAQ:BLTE) Stock Rating Upgraded by Wall Street Zen - Defense World
Belite Bio Inc Adr Stock (BLTE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):